Madrigal Pharmaceuticals (MDGL) Other Non Operating Income (2025 - 2026)
Madrigal Pharmaceuticals' (MDGL) quarterly Other Non Operating Income came in at -$2.1 million in Q1 2026, up 15.13% on a QoQ basis from -$2.5 million in Q4 2025.
Madrigal Pharmaceuticals (MDGL) Other Non Operating Income (2025 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has 2 years of Other Non Operating Income data on file, last reported at -$2.1 million in Q1 2026.
- On a quarterly basis, Other Non Operating Income changed N/A year-over-year to -$2.1 million in Q1 2026; TTM through Mar 2026 was -$4.9 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$2.8 million, changed N/A from the prior year.
- Other Non Operating Income for Q1 2026 stood at -$2.1 million, up from -$2.5 million in the prior quarter.
- Over the last five years, Other Non Operating Income for MDGL reached as high as -$42000.0 in Q2 2025 and fell as low as -$2.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Madrigal Pharmaceuticals | 15.79 Bn | 15.56 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.09 Mn |
| Dec 31, 2025 | -2.47 Mn |
| Sep 30, 2025 | -293,000.00 |
| Jun 30, 2025 | -42,000.00 |